G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
4.47 USD +4.20% Intraday chart for G1 Therapeutics, Inc. +29.57% +46.56%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Wedbush Lifts G1 Therapeutics' PT to $5 From $4, Adjusts Financing, Revenue Expectations; Keeps Outperform Rating MT
Transcript : G1 Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q4 Revenue $14.9M MT
G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024 CI
G1 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Top Midday Decliners MT
Caution Ahead of Key Inflation Data Weighs on Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday MT
Needham Adjusts G1 Therapeutics Price Target to $12 From $14, Maintains Buy Rating MT
G1 Therapeutics Gets Nod for Continuing Breast Cancer Study But CEO Notes Lack of 'Positive Interim Analysis'; Shares Drop Premarket MT
Wedbush Adjusts G1 Therapeutics' PT to $4 From $5, Keeps Outperform Rating MT
G1 Therapeutics Gets Continuation Recommendation From Data Monitoring Committee for Phase 3 Breast Cancer Study MT
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee CI
Transcript : G1 Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM
G1 Therapeutics, Inc. Announces Updates, Including Encouraging Preliminary Overall Survival Data from the Ongoing Phase 2 Trial of Trilaciclib in Combination with the ADC Sacituzumab Govitecan in Patients with TNBC CI
Simcere Pharma Gets Authorization to Produce Imported Cancer Drug in Hainan Facility MT
G1 Therapeutics, Inc.(NasdaqGS:GTHX) dropped from NASDAQ Biotechnology Index CI
G1 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : G1 Therapeutics, Inc., Q3 2023 Earnings Call, Nov 01, 2023
Earnings Flash (GTHX) G1 THERAPEUTICS Posts Q3 Revenue $12.3M, vs. Street Est of $14.2M MT
G1 Therapeutics, Inc. Lowers Net Revenue Guidance for the Full Year 2023 CI
G1 Therapeutics' COSELA(R) (Trilaciclib) Recommends in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology CI
North American Morning Briefing : Stock Futures -2- DJ
JPMorgan Downgrades G1 Therapeutics to Underweight From Neutral MT
G1 Therapeutics, Inc. Announces Resignation of Mark A. Velleca from the Board of Directors, Effective as of September 30, 2023 CI
Chart G1 Therapeutics, Inc.
More charts
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy designed to help and protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lung cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. Its Rintodestrant, is an oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2 (HER2)-breast cancer.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.47 USD
Average target price
8.5 USD
Spread / Average Target
+90.16%
Consensus
  1. Stock
  2. Equities
  3. Stock G1 Therapeutics, Inc. - Nasdaq
  4. News G1 Therapeutics, Inc.
  5. Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q3 Revenue $4.9M, vs. Street Est of $4.78M